Navigation Links
EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
Date:3/6/2008

ROCKVILLE, Md., March 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for the three months and twelve months ended December 31, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

For fiscal year 2007, revenues were $7.4 million versus $6.9 million for 2006. For the year ended December 31, 2007, the Company reported a net loss of ($23.4 million) or ($0.28) per share, versus ($50.9 million), or ($0.71) per share, for fiscal year 2006. As of December 31, 2007, the Company had cash and short-term investments of approximately $47.7 million.

Revenues for the fourth quarters ended December 31, 2007 and December 31, 2006 were both $3.9 million. The Company reported a net loss of ($4.0 million), or ($.05) per share for the three months ended December 31, 2007. This compares with a net loss of ($5.9 million), or ($0.08) per share for the fourth quarter 2006.

Dane R. Saglio, EntreMed Chief Financial Officer, commented, "Financial results for 2007 reflect an increase in both revenue and research and development expenses versus 2006. For the year, we recorded $7.4 million in royalty revenue, a small increase over 2006 royalty revenues of $6.9 million. While research and development expenses decreased in the fourth quarter, there was an increase of approximately $2 million for the full year as a result of the initiation of multiple Phase 2 trials for MKC-1 and Panzem(R) NCD, as well as the submission and acceptance of two IND filings in 2007. In addition to reporting our opera
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed to Present at ThinkEquity Partners 5th Annual Growth Conference
2. EntreMed Appoints Senior Vice President of Research and Development
3. EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076
4. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
5. EntreMed to Present at BIO CEO and Investor Conference
6. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
7. QMed, Inc. Reports July Medicare SNP Enrollments
8. Phlo Affiliate Reports Expanded Coverage to Oregon Border
9. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Carrington Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... ... July 02, 2015 , ... Sleepless nights will become obsolete as ... sleep, launched its Indiegogo campaign on June 23. Sound sleepers and the sleep deprived ... it effortless to use, while the integration of the Bluetooth speaker, alarm clock and ...
(Date:7/1/2015)... ... 2015 , ... The next-generation sequencing (NGS) clinical market is poised for huge ... industry. BCC Research reveals in its new report that the market drivers of this ... growing need for better diagnostics as part of a molecular diagnostics trend. , The ...
(Date:7/1/2015)... ... ... A newly launched business plan contest will ask startup companies from around the ... R&D. The Pistoia Alliance President’s Startup Challenge 2015 will see small and medium enterprises ... mentorship from a senior industry figure drawn from the Pistoia Alliance membership. , The ...
(Date:6/30/2015)... -- R-Japan Co.,Ltd. obtained the license of cell processing facility ... the Ministry of Health, Labour and Welfare Kinki Bureau of ... The fact that R- Japan received the ... and Medical Devices Agency (PMDA) on May 18, 2015 two ... cell manufacturing service to medical institutions. As of November 25, ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2
... Coulter,Inc. (NYSE: BEC ), a leading developer, ... innovate complex biomedical testing,announced today that Scott Garrett, ... at the 2007 Bear Stearns Healthcare,Conference on Tuesday, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) The live webcast ...
... Institute (TCI), a Los,Angeles-based DNA and genomics research ... new office in the heart of Boston,s legal ... effects of,chemical and toxic exposures on human health ... Reach Consulting, TCI now offers a,range of business, ...
... Biotech,Industry, Bank of America Investment, and UBS Global Life Sciences Investor ... ... 4 Trubion Pharmaceuticals,Inc. (Nasdaq: TRBN ) announced today that ... present an overview,of the company at three September investor conferences: ...
Cached Biology Technology:Beckman Coulter to Present at the Bear Stearns Healthcare Conference 2Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases 2Trubion Pharmaceuticals to Present at Upcoming Investor Conferences 2
(Date:6/17/2015)... JOSE, Calif. , June 17, 2015 /PRNewswire/ ... in human interface solutions, today announced that Xiaomi, ... adopted the Synaptics ® ClearPad ® ... of display driver integrated circuits (DDICs) for its ... Pro. By leveraging ClearPad for full in-cell display ...
(Date:6/16/2015)... 2015 /CNW Telbec/ - handyem Inc. and FlowMetric ... incorporation of handyem,s HPC-150 portable flow cytometer within ... This unprecedented model of mobile laboratory platform is ... Pennsylvania Convention Center, ... to 18 th 2015.  By virtue ...
(Date:6/16/2015)... June 16, 2015 Fingerprint Cards has ... sensors in the company,s portfolio from one of its module ... to mainly take place during the third quarter 2015. The ... Asia . Jörgen Lantto, CEO of FPC, ... the   growing interest from smartphone OEMs in integrating touch ...
Breaking Biology News(10 mins):Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2
... by Weill Cornell Medical College, the Ansary Symposium on ... leading figures in the field, including internationally known scientists, ... ethical issues in stem cell research. WHEN: ... Thursday, September 18, 8:00 AM-1:30 PM WHERE: ...
... physical mechanism behind the rapid transport of water ... Illinois have moved a step closer to ultra-efficient, ... and nano-manufacturing., "Extraordinarily fast transport of water in ... smoothness of the nanotube walls and their hydrophobic, ...
... Stuart A. Lipton, M.D., Ph.D., professor and director of ... Research Center at Burnham has been awarded $8 million, ... Science (CNS). The center will study potential environmental causes ... the National Institute of Environmental Health Sciences (NIEHS) of ...
Cached Biology News:Ansary Symposium on Stem Cell Research at Weill Cornell Medical College 2Simulations help explain fast water transport in nanotubes 2Burnham researcher awarded $8 million grant 2
... Anti-MAGE-D2/NRAGE-Like 2b GenBank Accession ... : peptide (C-QSQENQDTRPKVKAKK), corresponding to ... MAGE-D2/NRAGE-Like 2b Formulation: antiserum in ... glycerol Quality Assurance: routinely evaluated ...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Immunofixation Gel Kit, requires IF100 Reactivity: Human Applications: Immunofixation ...
...
Biology Products: